指南与共识消化、代谢与肾脏急症儿科与产科急症

指南第437号:子宫腺肌病的诊断与管理

Guideline No. 437: Diagnosis and Management of Adenomyosis.
指南 / 共识 · J Obstet Gynaecol Can · 2023-01-01
一句话结论所有有子宫的育龄患者应考虑子宫腺肌病;诊断可用经阴道超声或MRI,治疗按症状(出血、疼痛、不孕)个体化选择药物、介入或手术。

本指南由加拿大妇产科医师学会发布,旨在描述子宫腺肌病基于证据的诊断与管理。目标人群为所有有子宫的育龄患者。诊断选项包括经阴道超声和磁共振成像;治疗选项应根据症状(月经过多、疼痛和/或不孕)个体化,包括药物(非甾体抗炎药、氨甲环酸、复方口服避孕药、左炔诺孕酮宫内系统、地诺孕素、其他孕激素、促性腺激素释放类似物)、介入(子宫动脉栓塞)和手术(子宫内膜去除术、腺肌病病灶切除、子宫切除术)。指南采用GRADE方法评级证据质量和推荐强度。

要点

  • 目标人群为所有有子宫的育龄患者,诊断时需考虑子宫腺肌病。
  • 诊断选项包括经阴道超声和磁共振成像。
  • 治疗应根据症状(月经过多、疼痛和/或不孕)个体化选择。
  • 药物选项包括非甾体抗炎药、氨甲环酸、复方口服避孕药、左炔诺孕酮宫内系统、地诺孕素、其他孕激素、促性腺激素释放类似物。
  • 介入选项为子宫动脉栓塞;手术选项包括子宫内膜去除术、腺肌病病灶切除、子宫切除术。

适用人群与场景

  • 所有有子宫的育龄患者。

处置流程与药物剂量

  • 治疗选项应根据症状(月经过多、疼痛和/或不孕)个体化选择。
  • 药物选项包括非甾体抗炎药、氨甲环酸、复方口服避孕药、左炔诺孕酮宫内系统、地诺孕素、其他孕激素、促性腺激素释放类似物。
  • 介入选项包括子宫动脉栓塞。
  • 手术选项包括子宫内膜去除术、腺肌病病灶切除、子宫切除术。

研究设计与关键结果

  • 本指南由加拿大妇产科医师学会制定,检索MEDLINE Reviews、MEDLINE ALL、Cochrane、PubMed、EMBASE数据库,初始检索于2021年完成,2022年更新相关文章。
  • 纳入文章类型包括随机对照试验、Meta分析、系统评价、观察性研究和病例报告,检索并审阅所有语言的文章。
  • 作者采用GRADE方法对证据质量和推荐强度进行评级。

证据类型、等级与局限

  • 证据类型:指南;采用GRADE方法评级证据质量和推荐强度。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 原文未据此给出推荐。

指南或共识出处

  • 指南名称:Guideline No. 437: Diagnosis and Management of Adenomyosis;发布机构:加拿大妇产科医师学会(J Obstet Gynaecol Can);年份:原文未写明。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To describe the current evidence-based diagnosis and management of adenomyosis.

TARGET POPULATION: All patients with a uterus of reproductive age.

OPTIONS: Diagnostic options include transvaginal sonography and magnetic resonance imaging. Treatment options should be tailored to symptoms (heavy menstrual bleeding, pain, and/or infertility) and include medical options (non-steroidal anti-inflammatory drugs, tranexamic acid, combined oral contraceptives, levonorgestrel intrauterine system, dienogest, other progestins, gonadotropin-releasing analogues), interventional options (uterine artery embolization), and surgical options (endometrial ablation, excision of adenomyosis, hysterectomy).

OUTCOMES: Outcomes of interest include reduction in heavy menstrual bleeding, reduction in pelvic pain (dysmenorrhea, dyspareunia, chronic pelvic pain), and improvement in reproductive outcomes (fertility, miscarriage, adverse pregnancy outcomes).

BENEFITS, HARMS, AND COSTS: This guideline will benefit patients with gynaecological complaints that may be caused by adenomyosis, especially those patients who wish to preserve their fertility, by presenting diagnostic methods and management options. It will also benefit practitioners by improving their knowledge of various options.

EVIDENCE: Databases searched were MEDLINE Reviews, MEDLINE ALL, Cochrane, PubMed, EMBASE. The initial search was completed in 2021 and updated with relevant articles in 2022. Search terms included adenomyosis, adenomyoses, endometritis (used/indexed as adenomyosis before 2012), (endometrium AND myometrium) uterine adenomyosis/es, symptom/s/matic adenomyosis] AND [diagnosis, symptoms, treatment, guideline, outcome, management, imaging, sonography, pathogenesis, fertility, infertility, therapy, histology, ultrasound, review, meta-analysis, evaluation]. Articles included randomized controlled trials, meta-analyses, systematic reviews, observational studies, and case reports. Articles in all languages were searched and reviewed.

VALIDATION METHODS: The authors rated the quality of evidence and strength of recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. See online Appendix A (Table A1 for definitions and Table A2 for interpretations of strong and conditional [weak] recommendations).

INTENDED AUDIENCE: Obstetrician-gynaecologists, radiologists, family physicians, emergency physicians, midwives, registered nurses, nurse practitioners, medical students, residents, and fellows.

TWEETABLE ABSTRACT: Adenomyosis is common in reproductive-aged women. There are diagnostic and management options that preserve fertility available.

SUMMARY STATEMENTS: RECOMMENDATIONS.

来源:J Obstet Gynaecol Can,查看原文。版权归原作者所有。

参考来源

  1. Dason ES, Maxim M, Sanders A, et al. Guideline No. 437: Diagnosis and Management of Adenomyosis. J Obstet Gynaecol Can. 2023. PMID: 37244746. doi:10.1016/j.jogc.2023.04.008

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。